Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.84 |
| ▸ | MAPT | P10636 | 3/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | TSHR | P16473 | 2/20 | 0.84 |
| ▸ | BLM | P54132 | 2/20 | 0.84 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 2/20 | 0.84 |
| ▸ | MPO | P05164 | 1/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | APAF1 | O14727 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL289042 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL1120026 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL7327 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL475350 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL4732053 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL23141133 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL19161120 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL4732052 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL475349 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL289043 | 0.92 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069789-B1 | LOW SOLVENT COATING COMPOSITION | AKZO NOBEL COATINGS INT BV (NL) | 2024-05-22 | — | — | EP | disclosed |
| US-11577212-B2 | Stimuli-responsive micro-reservoirs for release of encapsulants | SAS Nanotechnologies Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2021110829-A1 | LOW SOLVENT COATING COMPOSITION | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2021-06-10 | — | — | WO | disclosed |
| EP-3823745-A1 | STIMULI-RESPONSIVE MICRO-RESERVOIRS FOR RELEASE OF ENCAPSULANTS | SAS Nanotechnologies LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020018555-A1 | STIMULI-RESPONSIVE MICRO-RESERVOIRS FOR RELEASE OF ENCAPSULANTS | SAS Nanotechnologies LLC (US) | 2020-01-23 | — | — | WO | disclosed |
| EP-2414464-B1 | ANTI-CORROSIVE COATING COMPOSITION | AKZO NOBEL COATINGS INT BV (NL) | 2013-08-28 | — | — | EP | disclosed |
| EP-2414464-A1 | ANTI-CORROSIVE COATING COMPOSITION | Akzo Nobel Coatings International B.V. (NL) | 2012-02-08 | — | — | EP | disclosed |
| US-20120025142-A1 | ANTI-CORROSIVE COATING COMPOSITION | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2012-02-02 | — | — | US | disclosed |
| WO-2010112605-A1 | ANTI-CORROSIVE COATING COMPOSITION | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2010-10-07 | — | — | WO | disclosed |
| CN-1241924-C | Method for preparing enkephalinase and angiotensin-converting enzyme inhibitor intermediate and its intermediate | AVENTIS PHARMACEUTICALS CORP (US) | 2006-02-15 | — | — | CN | disclosed |
| CN-1495186-A | Method for preparing enkephalinase and angiotensin-converting enzyme inhibitor intermediate and its intermediate | ���µ�˹ҩ�﹫˾ | 2004-05-12 | — | — | CN | disclosed |
| CN-1113894-C | Process for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof | AVENTIS PHARMA INC (US) | 2003-07-09 | — | — | CN | disclosed |
| CN-1170413-A | Process for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof | HOECHEST MARION ROUSSEL INC (US) | 1998-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11577212-B2 | Stimuli-responsive micro-reservoirs for release of encapsulants | ORAI1, CD44, VAPA | KDM4E 2671/4885MAPT 3648/4885KMT2A 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.